Michael J. Duffy

26.5k citations

264 papers · 19.1k indexed · 5 hit papers · h-index 77

Impact in

Cancer Research top 0.05%
- Protease and Inhibitor Mechanisms
- Cancer Genomics and Diagnostics
Oncology top 0.1%
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways

Papers in

Cancer Research 93
- Protease and Inhibitor Mechanisms 35
- Cancer Genomics and Diagnostics 29
- Breast Cancer Treatment Studies 21
Oncology 136
- HER2/EGFR in Cancer Research 56
- Cancer-related Molecular Pathways 30
- Peptidase Inhibition and Analysis 26

Co-authors: John Crown Norma O’Donovan Enda McDermott N. J. O’Higgins Peter A. Andreasen Patricia M. McGowan Lise Christensen Lars Kjøller
Journals: Clinical Chemistry (18 papers)International Journal of Cancer (15 papers)Journal of Clinical Oncology (15 papers)European Journal of Cancer (10 papers)Annals of Clinical Biochemistry International Journal of Laboratory Medicine (9 papers)
Partner nations: Ireland United States United Kingdom

In The Last Decade

Michael J. Duffy

261 papers receiving 18.6k citations

Hit Papers

5 papers align trajectories log scale

MYC as a target for cancer treatment 2021 · 296 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Cancer Treatment Reviews
2017 European Journal of Cancer
2001 Clinical Chemistry
2000 Breast Cancer Research
1997 International Journal of Cancer

Peers

Countries citing papers authored by Michael J. Duffy

Since Specialization

Citations

This map shows the geographic impact of Michael J. Duffy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Duffy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Duffy more than expected).

Fields of papers citing papers by Michael J. Duffy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Duffy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Duffy. The network helps show where Michael J. Duffy may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael J. Duffy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael J. Duffy Line = papers co-authored together Michael J. Duffy links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction Tumor Biology ·Michael J. Duffy	2023	24
2	Comparing functional and quality of life outcomes in transcatheter aortic valve implantation and surgical aortic valve replacement for aortic stenosis: a systematic review and meta-analysis BMC Cardiovascular Disorders ·Michael J. Duffy, Amy Lynch, Catriona Reddin, Conor Judge, Martin O’Donnell, Robert Murphy	2023	2
3	Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon? Clinical Chemistry and Laboratory Medicine (CCLM) ·Michael J. Duffy, Eleftherios P. Diamandis, John Crown	2021	43
4	Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells Cancers ·Patricia Gaule, Nupur Mukherjee, B. Corkery, Alex J. Eustace, Kathy Gately, Sandra Roche, Robert O’Connor, Kenneth J. O’Byrne, Naomi Walsh, Michael J. Duffy, John Crown, Norma O’Donovan	2019	19
5	The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells Translational Oncology ·Naoise C. Synnott, Stephen F. Madden, Vladimir J.N. Bykov, John Crown, Klas G. Wiman, Michael J. Duffy	2018	27
6	Validazione di nuovi marcatori di neoplasia: La posizione ufficiale dell'"European Group on Tumor Markers Pure Amsterdam UMC ·Michael J. Duffy, Catharine M. Sturgeon, György Sölétormos, Vivian Barak, Rafael Molina, Daniel F. Hayes, Eleftherios P. Diamandis, Patrick M. Bossuyt	2017	1
7	p53 in cancer: ready for therapeutic targeting? Translational Cancer Research ·Michael J. Duffy, Naoise C. Synnott, John Crown	2016	2
8	Precision treatment for cancer: Role of prognostic and predictive markers Critical Reviews in Clinical Laboratory Sciences ·Michael J. Duffy, John Crown	2014	27
9	Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer Clinical Chemistry ·Michael J. Duffy, John Crown	2013	34
10	Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer BMC Cancer ·Boyu Liu, Sarah Penny, Róisín Dolan, Catherine M. Kelly, Stephen F. Madden, Elton Rexhepaj, Donal J. Brennan, Amanda McCann, Fredrik Pontén, Mathias Uhlén, Radosław Zagożdżon, Michael J. Duffy, Malcolm Kell, Karin Jirström, William M. Gallagher	2013	43
11	HER-2 Signaling and Inhibition in Breast Cancer Current Cancer Drug Targets ·Brigid C. Browne, Neil A. O’Brien, Michael J. Duffy, John Crown, Norma O’Donovan	2009	92
12	Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer Clinical Cancer Research ·Donal J. Brennan, Elton Rexhepaj, Sallyann L. O’Brien, Elaine McSherry, Darran P. O’Connor, Ailís Fagan, Aedín C. Culhane, Desmond G. Higgins, Karin Jirström, Robert C. Millikan, Göran Landberg, Michael J. Duffy, Stephen M. Hewitt, William M. Gallagher	2008	71
13	ADAM-17 predicts adverse outcome in patients with breast cancer Annals of Oncology ·Patricia M. McGowan, Eadaoin McKiernan, Ferdia Bolster, Bríd M. Ryan, Arnold Hill, E. McDermott, Denis Evoy, N. J. O’Higgins, John Crown, Michael J. Duffy	2008	68
14	Use of a Panel of Novel Genes for Differentiating Breast Cancer from Non-Breast Tissues Tumor Biology ·P.H.E.O. van Mil, Norma O’Donovan, Deirdre Foley, Arnold Hill, Enda McDermott, N. J. O’Higgins, Michael J. Duffy	2007	8
15	CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance Clinical Cancer Research ·Donal J. Brennan, Karin Jirström, Åsa Kronblad, Robert C. Millikan, Göran Landberg, Michael J. Duffy, Lisa Rydén, William M. Gallagher, Sallyann L. O’Brien	2006	107
16	Carbonic anhydrase IX is a new independent prognostic marker in pre-menopausal breast cancer patients with 1 to 3 positive lymph nodes Cancer Research ·Donal J. Brennan, Åsa Kronblad, Karin Jirström, Göran Landberg, Michael J. Duffy, William M. Gallagher, Christopher Dong	2006	3
17	Estrogen Receptors: Role in Breast Cancer Critical Reviews in Clinical Laboratory Sciences ·Michael J. Duffy	2006	78
18	Expression of ADAM‐9 mRNA and protein in human breast cancer International Journal of Cancer ·János Hankiss, Norman McKie, Y. Buggy, Catherine Duggan, Arnold Hill, Enda McDermott, N. J. O’Higgins, Michael J. Duffy	2003	116
19	Biochemical markers in breast cancer: which ones are clinically useful? Clinical Biochemistry ·Michael J. Duffy	2001	79
20	Cellular oncogenes and suppressor genes as prognostic markers in cancer Clinical Biochemistry ·Michael J. Duffy	1993	30

About Michael J. Duffy

Michael J. Duffy is a scholar working on Cancer Research, Oncology, Immunology and Allergy, Pathology and Forensic Medicine and Hematology, having authored 264 papers that have together received 19.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (56 papers), Protease and Inhibitor Mechanisms (35 papers), Estrogen and related hormone effects (33 papers), Cancer-related Molecular Pathways (30 papers), Cancer Genomics and Diagnostics (29 papers), Peptidase Inhibition and Analysis (26 papers), Breast Cancer Treatment Studies (21 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). The work is most often cited by research in Cancer Research (7.0k citations), Oncology (8.0k citations), Immunology and Allergy (1.7k citations), Molecular Biology (9.0k citations) and Hematology (1.2k citations). Michael J. Duffy has collaborated with scholars based in Ireland, United States and United Kingdom. Frequent co-authors include John Crown, Norma O’Donovan, Enda McDermott, N. J. O’Higgins, Peter A. Andreasen, Patricia M. McGowan, Lise Christensen, Lars Kjøller, Naoise C. Synnott and Andrea Nicolini. Their work appears in journals such as Clinical Chemistry, International Journal of Cancer, Journal of Clinical Oncology, European Journal of Cancer and Annals of Clinical Biochemistry International Journal of Laboratory Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact